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De novo germline mutations in HRAS cause Costello syndrome, with >95% of the mutations
causingCostello syndromeaffecting amino acidposition12 (p.Gly12) or 13 (p.Gly13).We report
on a patient with de novo missense mutation causing an amino acid change at codon 146 of
HRAS, c.436G > C:p.Ala146Pro, who presented with subtle dysmorphic features, failure to
thrive, global developmental delay, and hypertrophic obstructive cardiomyopathy. Mutations
affecting codon 146 are observed in <1% of patients with Costello syndrome. From literature
search, therewere only twoother patients reportedwithmutations involving the same location.
We summarized and updated their findings, and discussed evidence to show that these patients
with less obvious signs of Costello syndrome may not necessarily run a more benign clinical
course.
K E YWORD S
Costello syndrome, HRAS mutation, RASopathy
1 | INTRODUCTION
Costello syndrome is a distinctive rare multisystem disorder compris-
ing of characteristic facial appearance (thin hair, coarse facies, thick
eyebrow, downslanted palpebral fissures, depressed nasal bridge, low
set ears, thick lips, and full cheeks), intellectual disability, growth
disturbance (biphasic pattern with intrauterine overgrowth and
postnatal failure to thrive that improves later in life), and tumor
predisposition (Hennekam, 2003; Johnson et al., 1998; Sammon et al.,
2012).
It is caused by HRASmutations exclusively (Aoki et al., 2005). The
disease-causingmutations result in amino acid substitutions that allow
constitutive or prolonged HRAS activation and subsequently dysre-
gulation of the Ras/mitogen activated protein kinase pathway (Gripp&
Lin, 2012). Over 90% of the mutations causing Costello syndrome
affect amino acid position 12 (p.Gly12) or 13 (p.Gly13) (Gripp & Lin,
1993). Among them, the three commonest mutations are p.Gly12Ser
(81.3% of total), p.Gly12Ala (7.2%), and p.Gly12Cys (2%). Mutations
affecting position 146 are rare and estimated to be seen in less than 1%
of patients (Sol-Church et al., 2009). Here, we report on a patient who
presented with failure to thrive and poor feeding, and was found to
have a novel p.Ala146Pro HRAS mutation by exome sequencing. We
reviewed the literature on patients with mutation involving this amino
acid position and obtained updated information on these patients.
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Our patient was born full term to a non-consanguineous Chinese
couple with a birth weight of 3.1 kg (25th centile). The prenatal course
was uneventful. He had poor feeding and failure to thrive, which did
not improve with dietetic intervention. At 6 months of age, he weight
was 4.96 kg (<3rd centile, 50th centile for 1.5months), with a height of
59 cm (<3rd centile, 50th centile for 2.5 months), and OFC of 43 cm
(25th centile). Initial physical examination by his pediatrician did not
reveal dysmorphic features.
Laboratory investigations showed metabolic acidosis with ele-
vated fasting lactate of 6.7 mmol/L. Common mitochondrial hotspot
mutation screening was negative. His initial thyroid function test was
suspicious of secondary hypothyroidism with thyroid stimulating
hormone of 0.35mIU/L and free thyroxine of 9.5 pmol/L. However, it
subsequently normalized and the thyroid-releasing-hormone
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FIGURE 1 Q3Clinical photographs of the index patient with p.Ala146Pro mutation of HRAS. A) Profile view of his face (taken at 36 months)
and B) Frontal view of his face (taken at 33 months). Note the fontal bossing, sparse and short hair, long eyelashes, deep set eyes, low set
ears, short nasal tip, long philtrum and the absence of full cheeks and full lips. C) Clinical photographs of his hand with absence of deep
palmer crease (taken at 36 months)
FIGURE 2 Screenshot of exome sequencing data of the index patient, showing a mutation in HRAS: c.436G>C:p,Ala146Pro (Figure 2A);
subsequent Sanger validation confirmed the findings in the index patient's peripheral blood sample (Figure 2B) and buccal swab (Figure 2C),
showing no evidence of mosaicism
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stimulation test was normal. There was transient neutropenia with
absolute neutrophil count of 0.25–0.5 × 10 ^ 9/L which resolved after
an episode of intercurrent illness. Other evaluations were essentially
unremarkable with normal biotinidase level, carnitine, and acylcarni-
tine profile, dried blood spot test for amino acid and urine for organic
acid. Brain MRI at 9 months showed an arachnoid cyst at the left
posterior cranial fossa measuring 1.2 cm. It was repeated at 2.5 years
showing similar findings.
He had moderate global developmental delay at 2.5 years and was
referred for genetic evaluation. Physical assessment showed frontal
bossing with sparse and short hair, long eyelashes, deep set eyes, low set
ears, short nasal tip, long philtrum, dry skin and a left sided inguinal hernia.
His cheeks and lips were not full, there was no deep palmer crease, no
evidence of pectus deformity and no kyphoscoliosis (Figure 1).
Initial genetic evaluation including karyotype, chromosomal
microarray, and methylation-specific multiplex ligation-dependent
probe amplification of chromosome 11, were normal. Singleton exome
sequencing (Mendelian inherited disorder panel, performed by
Genome Diagnostics Nijmegen) identified a mutation in HRAS:
c.436G>C:p.Ala146Pro, and subsequent parental testing confirmed
its de novo origin. A screenshot of the exome sequencing data and the
chromatogram of the subsequent Sanger validation showing the
mutation is shown in Figure 2A and B. Sanger confirmation using DNA
from the patient's buccal mucosa was also performed (Figure 2C),
showing similar findings as the peripheral blood sample and was not
suggestive of mosaicism.
He was found to have a cardiac murmur at 3 years. Echocardio-
gram showed asymmetrical left ventricular hypertrophy which was
more severe over the interventricular septum, systolic anterior motion
of the mitral valve as well as left ventricular outflow tract obstruction
with subvalvular aortic stenosis of 25–50mmHg, suggestive of
hypertrophic obstructive cardiomyopathy (HCM). He was monitored
conservatively with serial echocardiogram.
His global developmental delay persisted despite intensive
multidisciplinary training. At 4 years, he was walking fast, could
scribble, and build a tower of two bricks. He was able to identify five
body parts and hadmultiple single words. In terms of self-care skills, he
could feed himself with a spoon and indicate toilet needs. Overall, his
developmental profile was evenly distributed with a developmental
quotient below 50.
2.1 | Literature review and updated information on
previously reported patients
Only two other patients have been reported with HRAS mutations
involving codon 146 (Gripp et al., 2008; Zampino et al., 2007). Gripp
et al. (2008) reported a 5.5 years old girl with a p.Ala146Val mutation,
with mildly coarse facial features, short nasal tip, long philtrum, and
mildly prominent ears without strikingly deep palmer creases. She also
had global developmental delay, feeding difficulties requiring gastro-
stomy placement, history of treatment resistant tachycardia, growth
hormone deficiency, and HCM requiring myomectomy (Gripp et al.,
2008). Update from her primary care team revealed that she has not
developed further cardiac hypertrophy while on metoprolol, but
subsequent echocardiography noted mitral regurgitation at 8 years
and ventricular septal defect with mild aortic regurgitation at 10 years.
Brain imaging showed mild cerebellar tonsillar herniation (Gripp,
Hopkins, Doyle, & Dobyns, 2010). Osteoporosis was treated with
calciumand vitaminD supplements. Coxa valga did not requiremedical
intervention (Detweiler, Thacker, Hopkins, Conway, & Gripp, 2013).
She was in puberty had no menarche by age 14.5 years. Neuropsy-
chological evaluation at 9 years in her native language showed a full
scale IQ of 50 (verbal 53, non-verbal 51). Shewas originally studying in
a mainstream school at grade level. However, after a move and change
in the primary language spoken in school, learning difficulties resulted
in placement in a school for individuals with moderate intellectual
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FIGURE 3 Clinical photographs of the patient with p.Ala146Val mutation of HRAS as reported[Gripp et al., 2008]. A) Frontal view at age
9 years. B) Frontal view at 13 years
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disability, where she received an individualized education plan and had
a behavior specialist for a diagnosis of anxiety. At 14 years, she
attended a vocational school program and hoped to become an early
childhood teacher's assistant. Her dysmorphic features has remained
subtle (Figure 3A and B).
Zampino et al. (2007) reported another patient with p.Ala146Thr
mutation, with normal birth parameters, microcephaly, sparse thin but
not curly hair, normally located ears, less compromised growth, and
minor skin and joint involvement. Information regarding her systemic
involvement was lacking. Unfortunately, we were not able to obtain
further updates about the patient's current condition.
3 | DISCUSSION
Costello syndrome is a RASopathy with multisystemic involvement
including cardiac, orthopedic, neurological, growth, and musculoskel-
etal abnormalities as well as a predisposition for malignancies (Gripp &
Lin, 2012). Most patients with Costello syndrome harbor a mutation at
codon 12 of the HRAS, the most common one being p.Gly12Ser,
accounting for around 80% (Kerr et al., 2006;McCormick et al., 2013).
Alteration of glycine at position 12 or 13 of HRAS accounts for more
than 90% cases of Costello syndrome. The mutated protein becomes
bound to GTP in a constitutive or prolonged manner and activates
multiple downstream pathway including MAPK, PI-3 kinase, and
RalGDS (Aoki et al., 2005). This leads to altered cell growth,
proliferation, and cell death, which is consistent with many of the
clinical features seen in Costello syndrome.
Despite the overwhelming predominance of codon 12 or 13
related HRASmutation, other mutations have been reported, as in the
patient with substitution of alanine at position 146 by proline. To our
knowledge, this is the third reported patient with Costello syndrome
involving position 146 of HRAS. This residue is located within the G3
motif and is totally conserved in the RAS superfamily (Mitin, Rossman,
& Der, 2005). It is involved in the binding to the purine ring of GTP/
GDP and interacts directly with the guanine base (Wittinghofer &
Waldmann, 2000). Substitutions are predicted to destabilize HRAS
binding to either GTP or GDP, but since GTP has a higher
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TABLE 1 Comparing the Costello Syndrome Severity Scoring System (CSSSS) Score [McCormick et al., 2013] in the 2 reported patients withHRAS
p.Ala146 mutation and the index patient
p.A146V from Gripp (2008) and further updates
from the team
p.A146T from Zampino
(2007)
Index
patient
Feeding (1)
Feeding tube required (1) 1 1 0
Cardiac abnormalities (4)
Arrhythmia (1) 1 – 0
Ectopic atrial tachycardia/ multifocal atrial
tachycardia (1)
0 – 0
HCM (1) 1 – 1
Surgery for HCM (1) 1 – 0
Orthopedic abnormalities (2)
Archilles tendon lengthening surgery (1) 0 – 0
Orthopedic surgery, other (1) 0 – 0
Neurological abnormalities (3)
Chiari I malformation requiring surgery (1) 0 – 0
Hydrocephalus requiring surgery (1) 0 – 0
Seizures requiring medication (1) 0 – 0
Malignancies (4)
Primary occurrence (2) 0 – 0
Additional primary (2) 0 – 0
Bone density (1)
Z score <−3 or bisphosphonate infusion (1) 0 – 0
Short stature (1)
Height <−3 SD or growth hormone use (1) 1 – 1
Mortality (12)
Before age 1 year (8) 0 – 0
After age of 1 year (4) 0 – 0
Total score (28) 5 At least 1 2
“-” indicates information not available.
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concentration in the cytoplasm it will shift the equilibrium toward the
GTP bound active form (Zampino et al., 2007), acting inmuch the same
way as mutations in the position 12/13 hotspot.
Individuals with various mutations have an increased predisposi-
tion to malignancy, severe HCM, neonatal mortality, neurological
abnormality, and other complications (Kerr et al., 2006; McCormick
et al., 2013). Patients with the p.Gly12Cys mutation have less coarse
facial features subjectively and loose anagen hair with a matted
appearance. They also have significantly less multifocal atrial
tachycardia, ulnar wrist deviation, papilloma, and short stature (Gripp
et al., 2011). The expression of various downstream pathways,
however, were not shown to be different between genotypes in
functional studies (Gremer et al., 2010), and it is postulated that the
observed genotype–phenotype correlation may be secondary to cell
type specific effects (Gripp et al., 2011). However, genotype–
phenotype correlation of rare mutation like those involving codon
146 is given less attention simply because they are difficult to study
due to the rarity.
Comparing the three patients with HRAS mutations affecting
codon Ala 146, consistently the facial gestalt and physical findings
seems to be milder than patients with mutation at codon 12/13
hotspot and this includes less coarse facies, absence of thick lip,
and deep-palmer crease. Table 1 compared the clinical severity of
the three patients with codon 146 mutation, using the Costello
Syndrome Severity Scoring System (CSSSS) (McCormick et al.,
2013). As stated above, updated clinical information of the patient
with p.Ala146Thr is lacking. However, our patient with p.
Ala146Thr scored 2, which is equivalent to the mean CSSSS score
in patients with p.Gly12Ser mutation in their early childhood, while
the patient with p.Ala146Val already had a score of 5 at age
5 years, which is above the mean score of 3.743 in children with p.
Gly12Ser mutation at 10 years old (McCormick et al., 2013).
Therefore it is important to recognize that these patients with less
obvious signs of Costello syndrome may not necessarily run a more
benign clinical course.
Further management of this child would involve continual medical
surveillance for development and growth, malignancy, neurological,
and orthopedic complications (Gripp et al., 2010). Patients with
Costello syndrome are prone to development ofmalignancy, especially
rhabdomyosarcoma, neuroblastoma, bladder cell carcinoma, and
pituitary adenoma (Lin et al., 2011). In order to determine the
malignancy potential of theHRAS p.Ala146mutation, we searched the
COSMIC database (Bamford et al., 2004) in a similar way as Gripp et al.
(2008) for somatic mutations involving the HRAS as well as the highly
homologous KRAS in human cancer tissues. In a total of 25,736 and
26,421 samples analyzed for HRAS and KRAS principal transcript, 196
and 2,816 mutations were identified for HRAS and KRAS, respectively.
Whereas no mutation was identified in position 146 of HRAS, 68
mutationswere found involving position 146 of KRAS, with 52 cases of
p.Ala146Thr, 13 cases of p.Ala146Val, and three cases of p.Ala146Pro.
Such results support the need for vigilance regarding tumor
surveillance. It should be noted, however, that cancer surveillance in
Costello syndrome has been proven to be challenging, for example,
routine screening for neuroblastoma with urine for catecholamine is
not effective, as children with Costello syndrome are known to have
higher urinary excretion of catecholamines compared to the normal
population (Gripp, Kawame, Viskochil, & Nicholson, 2004).
Another importantfieldofsurveillance important isbrain imaging.Brain
malformation is highly prevalent in Costello syndrome, and most of it
pertains topostnatalonsetposterior fossacrowdingwithcerebellar tonsillar
herniation,whichmayprogresswith time and lead to hydrocephalus, Chiari
malformation, and syrinx formation (Gripp et al., 2010).
Yet another field of surveillance is growth. While Costello
syndrome is associated with failure to thrive per se, nearly half of
the patients also have concomitant partial growth hormone deficiency
(Rauen et al., 2008) and there have been multiple case reports on the
successful use with growth hormone (Blachowska et al., 2016; Stein,
Legault, Daneman, Weksberg, & Hamilton, 2004). However, growth
hormone replacement need be considered with caution in the setting
of HCM. Even though no significant difference in progression of HCM
was noted in children receiving or not receiving growth hormone
replacement (Rauen et al., 2008), re-emergence of previously resolved
HCM during growth hormone replacement has been reported
(Kobayashi, Cook, & Williams, 2010). Rapid progression of embryonic
rhabdomyosarcoma has also been reported while a patient with
Costello syndrome was put on growth hormone replacement (Kerr
et al., 2003). Thus a thorough evaluation should be performed before
commencement of recombinant growth hormone therapy.
In summary, we report on a patient with Costello syndrome with
the novel position 146 mutation, p.Ala146Pro, in HRAS. The physical
features suggestive of Costello syndrome were noted to be less
classical. Detailed genotype-phenotype analysis is not possible due to
the rarity of position 146 mutation, but current evidence suggests the
same health surveillance as in other patients with Costello syndrome
should be offered. Long-term follow up of these patients will be
necessary for more tailor-made recommendations.
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